NCT04729387: An ongoing trial by Novartis Pharmaceuticals
This trial is completed, but has been granted a delay in reporting its results.
It must report results 4 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04729387 |
|---|---|
| Title | EPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 22, 2021 |
| Completion date | April 21, 2023 |
| Required reporting date | April 21, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |